All In Biotech

Drug Trial Radar · NCT03473301

A Study of UCB and MSCs in Children With CP: ACCeNT-CP

A Phase I/II Study of Allogeneic Umbilical Cord Blood and Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Infusions in Children With Cerebral Palsy

Last checked: Nov 20, 2026Latest source record: Aug 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

91

Actual

Start

Apr 10, 2018

Primary completion

Feb 26, 2020

Study completion May 31, 2021

Sponsor

Lead sponsor
Joanne Kurtzberg, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Marcus Foundation
First posted
Mar 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 24 months, up to 60 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in children with cerebral palsy. In addition, this study will contribute much needed data to the clinical trials community on the natural history of the motor function in CP over short-term (less than 1 year) time periods relevant to the conduct of clinical trials and assess the safety of AlloCB and hCT-MSC infusion in children with cerebral palsy.

Conditions

  • Cerebral Palsy

Interventions

  • Infusion of allogeneic umbilical cord bloodBiological

    Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.

  • Infusion of MSCsBiological

    Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected ChangeTime frame: Baseline to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University Medical Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.